Creating a biorepository of biofluids and clinical data for ALS research
Official title: Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures
Run by Target ALS Foundation, Inc. · NCT05137665 · Data updated 2026-11-12
This study is collecting blood, spinal fluid, and urine samples from people with ALS and healthy individuals to help find new ways to understand and treat the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Target ALS Foundation, Inc. Academic / other |
| Locations | 12 sites (Phoenix, Arizona and 11 other locations) |
| Status | Recruiting |
| Started | June 1, 2021 |
| Main results expected | December 31, 2031 |
| Study ends | December 31, 2031 |
| Registry record updated | November 21, 2025 |
| Trial ID | NCT05137665 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 or older with a confirmed diagnosis of ALS and the ability to comply with study procedures.
✕Probably not a fit
Patients with neurological diseases other than ALS or those with known ALS-associated genetic mutations may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a biorepository of longitudinal biofluids, including blood, cerebrospinal fluid, and urine, linked to genetic and clinical information from patients with Amyotrophic Lateral Sclerosis (ALS) and healthy controls. Over a five-year period, 800 ALS patients and 200 healthy participants will be enrolled from various global sites. Participants will undergo regular clinical assessments and provide biofluid samples, which will be stored in a de-identified manner for future research. The goal is to facilitate the identification and validation of ALS biomarkers to enhance drug development.
Why it matters
Potential benefit: If successful, this study could significantly advance the understanding and treatment of ALS by providing critical biomarker data for future research.
How similar studies have gone: Previous studies have attempted similar approaches but have been limited in sample size, making this biorepository a potentially novel and valuable resource.
Who can join: the full rules
Show full inclusion / exclusion criteria
ALS Participants: 1. Age 18 or older. 2. A diagnosis of ALS in accordance with Gold Coast criteria. 3. Full Vital Capacity (FVC) of ≥30% or at the discretion of the Principal Investigator for the participant's predicted value for gender, height, and age at the time of screening. 4. Ability to provide informed consent and understand the purpose and risks of the study. 5. Ability to comply with study procedures and assessments, in the opinion of the Principal Investigator. Healthy Control Participants: 1. Age 18 or older. 2. No history of neurological disease, in the opinion of the Principal Investigator. 3. No known ALS- associated genetic mutations at the time of consent. 4. Ability to provide informed consent and understand the purpose and risks of the study. 5. Ability to comply with study procedures and assessments, in the opinion of the Principal Investigator.
Where it's running
-
Barrow Neurological Institute
Phoenix, Arizona, United States Recruiting -
University of California San Diego
San Diego, California, United States Recruiting -
Georgetown University
Georgetown, District of Columbia, United States Recruiting -
Mayo Clinic
Jacksonville, Florida, United States Recruiting -
Northwestern University
Chicago, Illinois, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Show 6 more locations
-
Washington University
St Louis, Missouri, United States Recruiting -
Columbia University
New York, New York, United States Recruiting -
Baylor College of Medicine
Houston, Texas, United States Recruiting -
University of Washington
Seattle, Washington, United States Recruiting -
Instituto Roosevelt
Bogotá, Colombia Recruiting -
CHALS-CCT UPR MScience
San Juan, Puerto Rico Recruiting
Study contacts
- Study coordinator: Laura Dugom, MPH
- Email: laura.dugom@targetals.org
- Phone: 919-440-2073
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How physical functioning relates to quality of life for people with ALS at TidalHealth
This study will see if physical functioning scores relate to quality of life for adults with ALS who receive care at TidalHealth Peninsula Regional.
-
Acamprosate for ALS with C9orf72 mutation
This study tests whether acamprosate can be safely used to see if it helps people with ALS who carry a C9orf72 mutation.
-
Observational study on amyotrophic lateral sclerosis
This study is collecting health information from people with ALS, those with related genetic mutations, and healthy volunteers to help improve treatments and understand the disease better.
-
Collecting data on neurodegenerative diseases progression markers
This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.
-
Understanding the variability in ALS through biomarkers
This study is trying to see how different biological markers can help us understand the varying symptoms of ALS in patients and group them based on their unique characteristics.
-
Creating a database to study variations in motor neuron diseases
This study is trying to learn more about the different types of motor neuron diseases in patients to better understand the condition and improve how we predict its course.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.